Laboratorio Reig Jofre, S.A. (RJF.MC)
EUR 2.73
(-0.36%)
EUR 2.73
(-0.36%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 73.18 Million EUR | 21.55% |
| 2022 | 60.21 Million EUR | -55.6% |
| 2021 | 135.61 Million EUR | 3.89% |
| 2020 | 130.53 Million EUR | 4.14% |
| 2019 | 125.35 Million EUR | 15.17% |
| 2018 | 108.84 Million EUR | 10.36% |
| 2017 | 98.62 Million EUR | 9.13% |
| 2016 | 90.37 Million EUR | 5.0% |
| 2015 | 86.06 Million EUR | 403.74% |
| 2014 | 17.08 Million EUR | -18.79% |
| 2013 | 21.03 Million EUR | -2.11% |
| 2012 | 21.49 Million EUR | -20.36% |
| 2011 | 26.98 Million EUR | -26.94% |
| 2010 | 36.93 Million EUR | -55.41% |
| 2009 | 82.83 Million EUR | -3.95% |
| 2008 | 86.24 Million EUR | 221.67% |
| 2007 | 26.81 Million EUR | -31.88% |
| 2006 | 39.35 Million EUR | 106.4% |
| 2005 | 19.06 Million EUR | 459.41% |
| 2004 | 3.4 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 16.69 Million EUR | 129.77% |
| 2024 Q1 | 20.96 Million EUR | 10.72% |
| 2024 Q2 | 18.44 Million EUR | -12.02% |
| 2023 Q1 | 20.07 Million EUR | 24.44% |
| 2023 Q3 | 41.36 Million EUR | 137.25% |
| 2023 FY | 73.18 Million EUR | 21.55% |
| 2023 Q2 | 17.43 Million EUR | -13.12% |
| 2023 Q4 | 18.93 Million EUR | -54.22% |
| 2022 Q4 | 16.12 Million EUR | -54.95% |
| 2022 FY | 60.21 Million EUR | -55.6% |
| 2022 Q3 | 35.8 Million EUR | 0.0% |
| 2021 Q3 | 33.35 Million EUR | -2.08% |
| 2021 Q2 | 34.06 Million EUR | 1.34% |
| 2021 Q1 | 33.61 Million EUR | -4.8% |
| 2021 FY | 135.61 Million EUR | 3.89% |
| 2021 Q4 | 34.58 Million EUR | 3.71% |
| 2020 Q3 | 30.28 Million EUR | -3.92% |
| 2020 FY | 130.53 Million EUR | 4.14% |
| 2020 Q1 | 33.43 Million EUR | -11.62% |
| 2020 Q2 | 31.51 Million EUR | -5.74% |
| 2020 Q4 | 35.3 Million EUR | 16.59% |
| 2019 Q1 | 28.72 Million EUR | -7.45% |
| 2019 FY | 125.35 Million EUR | 15.17% |
| 2019 Q4 | 37.83 Million EUR | 31.56% |
| 2019 Q3 | 28.75 Million EUR | -4.27% |
| 2019 Q2 | 30.04 Million EUR | 4.58% |
| 2018 FY | 108.84 Million EUR | 10.36% |
| 2018 Q1 | 27.07 Million EUR | -4.59% |
| 2018 Q4 | 31.03 Million EUR | 40.52% |
| 2018 Q3 | 22.08 Million EUR | -22.9% |
| 2018 Q2 | 28.64 Million EUR | 5.81% |
| 2017 FY | 98.62 Million EUR | 9.13% |
| 2017 Q4 | 28.37 Million EUR | 30.41% |
| 2017 Q3 | 21.75 Million EUR | -7.55% |
| 2017 Q2 | 23.53 Million EUR | -5.68% |
| 2017 Q1 | 24.95 Million EUR | 9.57% |
| 2016 Q3 | 20.19 Million EUR | -18.37% |
| 2016 Q4 | 22.77 Million EUR | 12.79% |
| 2016 FY | 90.37 Million EUR | 5.0% |
| 2016 Q1 | 22.66 Million EUR | -3.71% |
| 2016 Q2 | 24.73 Million EUR | 9.11% |
| 2015 FY | 86.06 Million EUR | 403.74% |
| 2015 Q2 | 22.44 Million EUR | 9.81% |
| 2015 Q3 | 19.63 Million EUR | -12.5% |
| 2015 Q4 | 23.54 Million EUR | 19.87% |
| 2015 Q1 | 20.44 Million EUR | 1852.89% |
| 2014 Q1 | 5.14 Million EUR | -4.44% |
| 2014 FY | 17.08 Million EUR | -18.79% |
| 2014 Q4 | 1.04 Million EUR | -76.14% |
| 2014 Q3 | 4.38 Million EUR | -32.56% |
| 2014 Q2 | 6.5 Million EUR | 26.32% |
| 2013 Q3 | 4.22 Million EUR | -29.66% |
| 2013 Q4 | 5.38 Million EUR | 27.5% |
| 2013 FY | 21.03 Million EUR | -2.11% |
| 2013 Q1 | 5.41 Million EUR | -45.59% |
| 2013 Q2 | 6 Million EUR | 10.91% |
| 2012 Q1 | 5.5 Million EUR | -50.37% |
| 2012 Q2 | 6.38 Million EUR | 15.85% |
| 2012 Q3 | 4.55 Million EUR | -28.56% |
| 2012 Q4 | 9.95 Million EUR | 118.43% |
| 2012 FY | 21.49 Million EUR | -20.36% |
| 2011 Q1 | 8.16 Million EUR | 0.0% |
| 2011 Q4 | 11.09 Million EUR | 0.0% |
| 2011 FY | 26.98 Million EUR | -26.94% |
| 2011 Q2 | 7.72 Million EUR | -5.33% |
| 2010 Q1 | 9.94 Million EUR | 0.0% |
| 2010 Q2 | 8.89 Million EUR | -10.6% |
| 2010 FY | 36.93 Million EUR | -55.41% |
| 2009 Q1 | 21.65 Million EUR | 0.0% |
| 2009 FY | 82.83 Million EUR | -3.95% |
| 2008 FY | 86.24 Million EUR | 221.67% |
| 2007 FY | 26.81 Million EUR | -31.88% |
| 2006 FY | 39.35 Million EUR | 106.4% |
| 2005 FY | 19.06 Million EUR | 459.41% |
| 2004 FY | 3.4 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Almirall, S.A. | 668.75 Million EUR | 89.057% |
| Faes Farma, S.A. | 127.02 Million EUR | 42.388% |